Clinical trial
Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of the Intravenous Administration of SNS-595 as Second-Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00252382 is registered in ClinicalTrials.gov with Sunesis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of the Intravenous Administration of SNS-595 as Second-Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Lead sponsor
- Sunesis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 27, 2005
- Completion date
- November 29, 2007
- Enrollment
- 31 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.